123,000 research outputs found
L'"erreur du stimulus"
No full textBozzi Paolo. L'"erreur du stimulus". In: Intellectica. Revue de l'Association pour la Recherche Cognitive, n°28, 1999/1. Présences de la Gestalt, sous la direction de R. Casati. pp. 139-145
Quality of life and families caregiving persons with dementia: a multidimensional analysis.
No full textIncontri di Fisica delle Alte Energie - IFAE 2012 - Il Nuovo Cimento C Year 2013 - Issue 1 - January-February - Year 2013 Vol 036 -
No full textIncontri di Fisica delle Alte Energie 201
Safety of escitalopram in pregnancy: a case series
No full textCesario Bellantuono, Francesca Bozzi, Laura Orsolini Psychiatric Unit and DEGRA Center, United Hospital and Academic Department of Experimental and Clinical Medicine, Polytechnic University of Marche, Ancona, Italy Background: The aim of this paper is to report maternal and neonatal outcomes in pregnant women treated with escitalopram during pregnancy and breastfeeding. Methods: Women enrolled in the DEGRA Database at the Clinic of Affective Disorders in Pregnancy and Postpartum in Italy, treated during pregnancy with escitalopram and followed up throughout pregnancy, were included in this study. All patients provided written informed consent and the study was approved by the local ethics committee. Psychiatric diagnoses were assessed using the Structured Clinical Interview for DSM-IV (Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition) Axis I Disorders and symptoms were assessed using the Hamilton Rating Scale for Depression (17 items) and Hamilton Rating Scale for Anxiety (14 items). Clinical and sociodemographic characteristics as well as maternal and neonatal outcomes were recorded. Results: The case histories of seven pregnant women treated for depression and/or anxiety disorders with escitalopram were reported. Four women were also treated with benzodiazepines. All pregnancies were full-term and all newborns had normal Apgar scores. There were no major malformations or miscarriages following exposure to escitalopram. Mild withdrawal syndrome was reported only in a newborn who was also exposed to a benzodiazepine. Two infants exposed to escitalopram during breastfeeding did not show any health problems. Conclusion: Our experience with use of escitalopram in pregnant women did not reveal any maternal or neonatal concerns. However, considering the few cases analyzed and the paucity of published literature, no conclusions can be drawn on its safety profile in pregnancy and breastfeeding. Keywords: escitalopram, pregnancy, breastfeeding, major malformations, perinatal complication
Parton density function uncertainties on the W boson mass measurement from the lepton transverse momentum distribution
No full textWe study the charged current Drell-Yan process and we evaluate the proton parton densities uncertainties on the lepton transverse momentum distribution and their impact on the determination of the W-boson mass. We consider the global PDF sets CT10, MSTW2008CPdeut, NNPDF2.3, NNPDF3.0, MMHT2014, and apply the PDF4LHC recipe to combine the individual results, obtaining an uncertainty on MW that ranges between +-18 and +-24 MeV, depending on the final state, collider energy and kind. We discuss the dependence of the uncertainty on the acceptance cuts and the role of the individual parton densities in the final result. We remark that some PDF sets predict an uncertainty on MW of O(10 MeV); this encouraging result is spoiled, in the combined analysis of the different sets, by an important spread of the central values predicted by each group
Action of botulinum neurotoxins in the central nervous system: antiepileptic effects
No full textBotulinum neurotoxins (BoNTs) are metalloprote-ases which act on nerve terminals and cause a long-lasting inhibition of neurotransmitter release. BoNTs act by cleaving core proteins of the neurotransmitter release machinery, namely the SNARE (soluble NSF-attachment receptors) proteins. The action of BoNTs in the peripheral nervous system (PNS) has been extensively documented, and knowledge gained in this field laid the foundations for the use of BoNTs in human disorders characterized by hyperfunction of peripheral nerve terminals. Much less is known about the action of BoNTs on the central nervous system (CNS). In vitro studies have demonstrated that BoNTs can affect the release of several neurotransmitters from central neurons. Recent studies have provided the first characterization of the effects of BoNT/E on CNS neurons in vivo. It has been shown that BoNT/E injected into the rat hippocampus inhibits glutamate release and blocks spike activity of pyramidal neurons. Intrahippocampal ..
- …
